Corpus overview


MeSH Disease

Human Phenotype



There are no seroprevalence terms in the subcorpus

    displaying 1 - 2 records in total 2
    records per page

    The Writing On The Wall Intravitreal Injection Compliance During The COVID-19 Pandemic and Its Foreseeable Consequences

    Authors: Lauren M Wasser; Yishay Weill; Koby Brosh; Itay Magal; Michael Potter; Israel Strassman; Evgeny Gelman; Meni Koslowsky; David Zadok; Joel Hanhart

    doi:10.21203/ Date: 2020-08-04 Source: ResearchSquare

    Background: Intravitreal injections (IVI) of anti-vascular endothelial growth factor (anti-VEGF) agents have become the most prevalent intraocular procedure as they represent the major therapeutic modality for prevalent retinal conditions such as age TRANS-related macular degeneration MESHD macular degeneration HP (AMD) and diabetic retinopathy MESHD retinopathy HP. Effective therapy requires adherence to a schedule of iterative IVI as well as routine clinic appointments. The ongoing Coronavirus disease MESHD 2019 (COVID-19) pandemic has resulted in the reduction of attendance at scheduled clinics visits and IVI. In this study we attempted to analyze the effect of COVID-19 on compliance with anti-VEGF therapy.Methods: A total of 636 eyes received injections during a four-week period of the COVID-19 outbreak in the Retina Clinic. The number of clinic visits for IVI during one month from March 15 to April 14 of 2020 was compared to the similar time period in each of the last four years.Results: The study demonstrates a decrease in clinic visits for IVI when compared with the same four-week interval in the four previous years. Based on the trend of the previous four years, 10.2% of the year’s total was expected for this time period. Using this model, the 636 reported number of injections for the March-April, 2020 period was ~ 5%. This represents a decrease of ~50% of the expected IVI for this time period.Conclusion: The COVID-19 outbreak in Israel severely impacted compliance with anti-VEGF treatments.

    Identification of Immune complement function as a determinant of adverse SARS-CoV-2 infection MESHD outcome

    Authors: Vijendra Ramlall; Phyllis M. Thangara; Nicholas P. Tatonetti; Sagi D. Shapira

    doi:10.21203/ Date: 2020-05-01 Source: ResearchSquare

    Understanding the pathophysiology of SARS-CoV-2 infection MESHD is critical for therapeutics and public health intervention strategies. Viral-host interactions can guide discovery of regulators of disease MESHD outcomes, and protein structure function analysis points to several immune pathways, including complement and coagulation, as targets of the coronavirus proteome. To determine if conditions associated with dysregulation of the complement or coagulation systems impact adverse clinical outcomes associated with SARS-CoV-2 infection MESHD, we performed a retrospective observational study of 11,116 patients suspected of SARS-CoV-2 infection MESHD. We found that history of macular degeneration MESHD macular degeneration HP (a proxy for complement activation disorders) and history of coagulation disorders ( thrombocytopenia MESHD thrombocytopenia HP, thrombosis MESHD, and hemorrhage MESHD) are risk factors for morbidity and mortality in SARS-CoV-2 infected patients – effects that could not be explained by age TRANS or sex. In addition, using data from the UK Biobank, we implemented a candidate driven approach to evaluate linkage between severe SARS-CoV-2 disease MESHD and genetic variation associated with complement and coagulation pathways. Among our findings, our scan identified an eQTL for CD55 (a negative regulator of complement activation) and SNPs in Complement Factor H (CFH) and Complement Component 4 Binding Protein Alpha (C4BPA), which play central roles in complement activation and innate immunity and were previously linked to Age TRANS Related Macular Degeneration MESHD Macular Degeneration HP (AMD) in a Genome-Wide Association Study (GWAS). In addition to providing evidence that complement function modulates SARS-CoV-2 infection MESHD outcome, the data point to several putative genetic markers of susceptibility. The results highlight the value of using a multi-modal analytical approach, combining molecular information from virus protein structure-function analysis with clinical informatics and genomics to reveal determinants and predictors of immunity, susceptibility, and clinical outcome associated with infection MESHD.

The ZB MED preprint Viewer preVIEW includes all COVID-19 related preprints from medRxiv and bioRxiv, from ChemRxiv, from ResearchSquare, from arXiv and from and is updated on a daily basis (7am CET/CEST).



MeSH Disease
Human Phenotype

Export subcorpus as Endnote

This service is developed in the project nfdi4health task force covid-19 which is a part of nfdi4health.

nfdi4health is one of the funded consortia of the National Research Data Infrastructure programme of the DFG.